• Explore /
  • Poster
  • / Nab-paclitaxel plus anti–PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).

Nab-paclitaxel plus anti–PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).

Abstract Poster

Authors

null

Xiaofen Li

Department of Abdominal Oncology, West China Hospital, West China School of Clinical Medicine, Sichuan University, Chengdu, China;

Xiaofen Li , Nan Zhou , Yu Yang , Hongfeng Gou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

ChiCTR2100052118

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 564)

DOI

10.1200/JCO.2023.41.4_suppl.564

Abstract #

564

Poster Bd #

D16

Abstract Disclosures

Similar Posters

First Author: John Ebben

First Author: Jia Fan

First Author: Richard D. Kim

First Author: Zhen-gang Yuan